National Cancer Institute clinical trials

National Cancer Institute Clinical Trials Listing http //www.cancer.gov/clinical trials Center Watch Clinical Trials Listing Service http / / w ww.centerwatch. com... 

Clinical results for Lutrin have been published for locally recurrent breast cancer after unsuccessful radiotherapy or chemotherapy [72]. Lutrin has also been selected by the National Cancer Institute for trials in primary cancers of the bladder, oesophagus, head and neck, and ovaries. 

A comprehensive website summarizing the status of tumor antiangiogenic compounds in various stages of clinical trial is maintained by the National Cancer Institute at www.cancer.gov/clinicaltrials/developments/ anti-angio-table. Following is a survey of the most important substances currently in clinical development. 

PDQ Physician Data Query. PDQ is an online database developed and maintained by the National Cancer Institute. Designed to make the most current, credible, and accurate cancer information available to health professionals and the public, PDQ contains peer-reviewed summaries on cancer treatment, screening, prevention, genetics, and supportive care a registry of cancer clinical trials from around the world and directories of physicians, professionals who provide genetics services, and organizations that provide cancer care. Most of this information is available on the CancerNet Web site, and more specific information about PDQ can be found at http //cancemet.nd.nih.gov/pdq.html. [NIH]... 

Shepherd, F.A. et al., A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Croup (NCIC CTC) trial, Proc. Am. Soc. Clin. Oncol., 22(SuppL), 14S, Abstr. 7022, 2004. 

Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993 ll(2) 336-344. 

Early interest concerning the role of cisplatin as a radiosensitizer led to several randomized clinical trials. A National Cancer Institute (NCI) sponsored intergroup trial of 371 unresectable patients comparing conventional radiation therapy to the use of weekly low dose cisplatin (20 mg/m2) as an adjunct to the same regimen of conventional radiotherapy found no statistical difference in complete response (34% for the concurrent modality vs 30% in the radiation therapy alone arm) or overall survival (24). The final results of this study were never published. 

IL-4 Clinical trials Cancer (various) Schering Plough and National Cancer Institute, USA... 

Brown M, Click HA, Harrell F, Herndon J, McCabe M, Moinpour C et al. Integrating economic analysis into cancer clinical trials the National Cancer Institute-American Society of Clinical Oncology Economics workbook. J Natl Cancer InstMonogr 1998 24 1-28. 

Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarba-zine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996 14(7) 2083-90. 

Motexafin lutetium is also in clinical trials, having completed several Phase I and II studies. The completed trials are for the photodynamic treatment of recurrent breast cancer [41,42], light-based treatment of choroidal neovascularization, [43] and the photoangioplastic reduction of atherosclerotic plaque in peripheral [19,44] and coronary arterial disease [20,45], On the basis of these studies, MLu (Antrin Phototherapy) is currently being developed for the treatment of atherosclerotic plaque. Additionally, the National Cancer Institute is testing MLu for the PDT based treatment of prostate [46,47] and cervical cancers. 

Goss G et al (2009) A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer a study of the national cancer institute of Canada clinical trials group. Eur J Cancer 45 782-788... 

In recent years, cA-dichlorodiammineplatinum(II) has been tested against a wide variety of animal tumors [2], While this drug is by no means the most active of the platinum complexes, it was the first chosen by the National Cancer Institute to be slated for clinical trials. This fact made studies with this drug more imperative, and most further research making up the bulk of the, by now, over 600 papers in the field, are concerned with it. A tabulation of the best animal test results is shown in the Table. 

The discovery of Taxol is a fruit of a National Cancer Institute (NCI)-sponsored project on identification of antitumor agents from natural resources. Bioassay-guided fractionation led to the isolation of this unique compound from Taxus bre-vifolia (pacific yew). Wani et al. also identified another famous antitumor natural product camptothecin. Unlike camptothecin, which was abandoned in the phase of clinical trial because of its severe toxicity, Taxol was almost discarded at the preliminary phase because it only exhibited moderate in vitro activity toward P388, a murine leukemia cell line that was used in the standard evaluation system by NCI researchers at that time. However, it was rescued by a subsequent finding of its strong and selective antitumor activities toward several solid tumors, and more... 

El has been investigated in anticancer clinical trials at the U.S. National Cancer Institute (NCI), particularly for the treatment of myeloid leukemia (66, 67). However, its side effects still remain an issue. Thus, the authors have continued to study new natural constituents of Cephalotaxus species and to develop new analogs on the basis of SAR studies, as presented in a review by Itokawa et al. (68). 

---